Jiangsu Hengrui Pharmaceuticals announced that its subsidiaries Shanghai Hengrui Pharmaceuticals Co., Ltd. and Shandong Shengdi Pharmaceuticals Co., Ltd. have received the Drug Clinical Trial Approval Letter from the National Medical Products Administration (NMPA) for HRS-2129 tablets and will conduct clinical trials in the near future. HRS-2129 tablets are intended for treating acute and chronic pain.
恒瑞医药：子公司获得药物临床试验批准通知书
Jiangsu Hengrui Pharmaceuticals: Subsidiary received drug clinical trial approval letter.
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
Hot News
Updated